According to Repligen 's latest financial reports the company's current earnings (TTM) are $66.08 M. a decrease over its 2022 earnings that were of $0.22 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 | $66.08 M | -70% |
2022 | $0.22 B | 33.37% |
2021 | $0.16 B | 131.52% |
2020 | $71.35 M | 101.31% |
2019 | $35.44 M | 25.93% |
2018 | $28.14 M | 105.61% |
2017 | $13.68 M | -11.46% |
2016 | $15.46 M | 14.91% |
2015 | $13.45 M | 20.26% |
2014 | $11.18 M | -51.49% |
2013 | $23.06 M | 90.98% |
2012 | $12.07 M | |
2010 | $0.17 M | -103.81% |
2009 | -$4.59 M | -223.84% |
2008 | $3.7 M | |
2006 | -$2.49 M | 229.64% |
2005 | -$0.76 M | -89.16% |
2004 | -$6.97 M | -16.86% |
2003 | -$8.38 M | 88.72% |
2002 | -$4.44 M | -27.88% |
2001 | -$6.16 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | 4,843.78% | ๐บ๐ธ USA |
Thermo Fisher Scientific TMO | $6.29 B | 9,430.44% | ๐บ๐ธ USA |
General Electric GE | $11.30 B | 17,013.33% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $8.44 B | 12,671.82% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | -$0.12 B | -280.06% | ๐บ๐ธ USA |
Novavax NVAX | -$0.53 B | -899.93% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $0.33 B | 409.81% | ๐บ๐ธ USA |
Bio-Techne TECH | $0.26 B | 302.14% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $0.18 B | 185.34% | ๐บ๐ธ USA |
Charles River Laboratories
CRL | $0.58 B | 779.63% | ๐บ๐ธ USA |